Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

AEZS
Aeterna Zentaris, Inc.
stock NASDAQ

Inactive
Aug 8, 2024
5.72USD+5.926%(+0.32)7,563
Pre-market
0.00USD-100.000%(-5.40)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
04:45PM EST  Aeterna Zentaris Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule   Benzinga
04:05PM EST  Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain   GlobeNewswire Inc
08:20AM EST  Aeterna Zentaris Provides Business Outlook And Outlines Pipeline Priorities   Benzinga
08:05AM EST  Company advancing diversified portfolio focused on areasof significant unmet medical need Supported by solid financial position with cash to fund operations beyond 2023   GlobeNewswire Inc
Jan 20, 2022
08:05AM EST  Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET   GlobeNewswire Inc
Jan 5, 2022
08:36AM EST  Aeterna Zentaris to Present at the H.C. Wainwright BioConnect   GlobeNewswire Inc
Dec 23, 2021
04:05PM EST  Aeterna Zentaris Appoints Giuliano La Fratta As Chief Financial Officer   Benzinga
04:05PM EST  Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional servicessectors   GlobeNewswire Inc
Nov 5, 2021
09:32AM EDT  AEterna Zentaris Q3 EPS $(0.01) Up From $(0.02) YoY, Sales $600.00K Up From $128.00K YoY   Benzinga
Oct 25, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021   Benzinga
06:25AM EDT  HC Wainwright & Co. Initiates Coverage On AEterna Zentaris with Buy Rating, Announces Price Target of $2   Benzinga
Sep 8, 2021
08:00AM EDT  Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual   GlobeNewswire Inc
Aug 4, 2021
05:15PM EDT  AEterna Zentaris Q2 Sales $600.00K Up From $68.00K YoY   Benzinga
04:05PM EDT  Company continues to advance clinical and preclinical programswith its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need   GlobeNewswire Inc
Jul 29, 2021
08:05AM EDT  Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum   GlobeNewswire Inc
Jun 9, 2021
12:24PM EDT  Mid-Day Market Update: United Natural Foods Falls On Sales Miss; Aethlon Medical Shares Jump   Benzinga
Jun 7, 2021
08:05AM EDT  Dr. Levyis a well-established neuroimmunologistwith extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders   GlobeNewswire Inc
Jun 3, 2021
08:05AM EDT  Aeterna Zentaris Announces Final Settlement of Previously   GlobeNewswire Inc
May 17, 2021
10:13AM EDT  Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis   Benzinga
08:12AM EDT  Aeterna Zentaris Announces Start Of Preclinical Development Of Macimorelin At The University Of Queensland As A Potential New Treatment Option For Patients With Amyotrophic Lateral Sclerosis   Benzinga
08:05AM EDT  - Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the treatment of ALS   GlobeNewswire Inc
May 13, 2021
09:33AM EDT  Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis   Benzinga
08:05AM EDT  Aeterna Zentaris Reports Commencement Of Pivotal Phase 3 DETECT-Trial For Diagnosis Of Childhood-Onset Growth Hormone Deficiency   Benzinga
08:05AM EDT  Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")   GlobeNewswire Inc
May 10, 2021
08:05AM EDT  Live video webcast with CEO, Dr. Klaus Paulini, onMonday, May 17, 2021 at 8:45 AM ET   GlobeNewswire Inc
May 6, 2021
08:22AM EDT  Aeterna Zentaris Announces Selection Of A Development Candidate In DC-PTH Program For Potential Treatment Of Primary Hypoparathyroidism   Benzinga
08:05AM EDT  In collaboration, Aeterna and The University of Sheffield, UK have selected ? the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study. ? AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.   GlobeNewswire Inc
May 5, 2021
08:09AM EDT  AEterna Zentaris Q1 EPS $(0.02) Down From $0.04 YoY, Sales $600.00K Down From $1.09M YoY   Benzinga
08:05AM EDT  Q12021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets   GlobeNewswire Inc
May 3, 2021
08:05AM EDT  Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology   GlobeNewswire Inc
Apr 28, 2021
08:05AM EDT  Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced its Annual General Meeting ("AGM") will be held on May 5, 2021 at 10:00 a.m. ET. Due to the impact of the COVID-19 pandemic, the meeting will be held virtually.   GlobeNewswire Inc
Mar 25, 2021
08:07AM EDT  AEterna Zentaris Q4 EPS $(0.02) Up From $(0.05) YoY, Sales $2.40M Up From $18.00K YoY   Benzinga
08:05AM EDT  Company executing on growth strategy to build-out pipeline of development assets   GlobeNewswire Inc
Mar 22, 2021
04:07PM EDT  Aeterna Zentaris Reports Regained Nasdaq Compliance   Benzinga
04:05PM EDT  Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price   GlobeNewswire Inc
Mar 15, 2021
09:11AM EDT  Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine Candidate   Benzinga
08:19AM EDT  Aeterna Zentaris Announces Exclusive License Agreement And Research Contract With Julius-Maximilians-University Wuerzburg For Development Of A Potential Oral Prophylactic Bacterial Vaccine Against COVID-19; Financial Details Not Disclosed   Benzinga
08:05AM EDT  - Company secures next step to continue to build-out pipeline of assets   GlobeNewswire Inc
Mar 11, 2021
08:15AM EST  Aeterna Zentaris Initiates Preclinical Program For Potential Treatment Of Primary Hypoparathyroidism; Co. Obtains Exclusive Patent From University of Sheffield For 100,000 Plus Milestones   Benzinga
08:05AM EST  Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will initially be studied by Aeterna for the potential therapeutic treatment of primary hypoparathyroidism   GlobeNewswire Inc
Feb 24, 2021
08:05AM EST  Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the Company), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.   GlobeNewswire Inc
Feb 19, 2021
01:25PM EST  Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal   GlobeNewswire Inc
Feb 17, 2021
07:27AM EST  The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal   Benzinga
05:54AM EST  Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to 20.509M Priced @$1.45/Share   Benzinga
Feb 16, 2021
10:00PM EST  Aeterna Zentaris Increases Previously Announced Bought Deal   GlobeNewswire Inc
05:21PM EST  Aeterna Zentaris Announces $10M Bought Deal Offering Of Common Shares; 6,896,552 Shares At $1.45/Share   Benzinga
05:19PM EST  Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of   GlobeNewswire Inc
Feb 9, 2021
10:23AM EST  Mid-Morning Market Update: Markets Mixed; Bitcoin Hits Record High   Benzinga
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 2, 2021
07:31AM EST  Aeterna Zentaris Reports Evaluation, Potential Development Of Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Deal With Julius-Maximilians-University Wuerzburg   Benzinga
07:30AM EST  - Company secures next step to continue to build-out pipeline of assets   GlobeNewswire Inc
Jan 28, 2021
08:07AM EST  Aeterna Zentaris Announces It Has Licensed Exclusive Worldwide Rights To Develop, Manufacture And Commercialize Targeted, Highly Specific, Autoimmunity Modifying Proteins For The Potential Treatment Of MOSD From The Julius-Maximilians-University Wuerzburg   Benzinga
08:05AM EST  Aeterna Zentaris Expands Orphan Drug Development Pipeline with   GlobeNewswire Inc
Jan 26, 2021
04:05PM EST  Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain   GlobeNewswire Inc
Jan 15, 2021
08:05AM EST  Live video webcast with CEO, Dr. Klaus Paulini, onWednesday, January 20th at 12:00 PM ET   GlobeNewswire Inc
Jan 5, 2021
08:05AM EST  Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the Company), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021.   GlobeNewswire Inc
Dec 7, 2020
08:15AM EST  Aeterna Zentaris Announces European Licensing Agreement With Consilient Health Ltd. For Commercialization Of Macimorelin; Consilient to Make 1M Upfront Payment And Pay Aeterna 10%-20% Royalties On Macimorelin Sales   Benzinga
08:05AM EST  Aeterna Zentaris Announces European Licensing Agreement with   GlobeNewswire Inc
Nov 16, 2020
08:23AM EST  Aeterna Zentaris Amends License Agreement With Novo Nordisk For Commercialization And Development Of Macimorelin; Co. To Receive 5M Upfront Payment   Benzinga
08:05AM EST  - Company to receive upfront payment of 5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund 9 million of the budgeted AEZS-130-P02 (Study P02) clinical trial costs for childhood-onset growth hormone deficiency expected to be initiated in Q1 2021   GlobeNewswire Inc
Nov 6, 2020
08:36AM EST  AEterna Zentaris Q3 EPS $(0.02), Same YoY, Sales $100.00K Down From $283.00K YoY   Benzinga
08:35AM EST  Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (Study P02) expected to commence in Q1 2021   GlobeNewswire Inc
Nov 3, 2020
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Oct 9, 2020
08:01AM EDT  Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc. - AEZS   PR Newswire
Sep 16, 2020
08:14AM EDT  Aeterna Zentaris Provides Corporate Update   Benzinga
08:05AM EDT  Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth   GlobeNewswire Inc
Sep 9, 2020
08:00AM EDT  - Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT -   GlobeNewswire Inc
Sep 8, 2020
08:12AM EDT  Aeterna Zentaris Highlights Presentation Of Results From First Pediatric Study Of Macimorelin At 22nd European Congress Of Endocrinology   Benzinga
08:05AM EDT  - PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults -   GlobeNewswire Inc
Aug 30, 2020
08:24AM EDT  The Week Ahead In Biotech (Aug. 30- Sept. 5): Bristol-Myers Squibb FDA Decision, Adcom Review For Glaxo, Amarin Vascepa Hearing   Benzinga
Aug 6, 2020
08:38AM EDT  AEterna Zentaris Q2 EPS $(0.15) Down From $0.01 YoY, Sales $68.00K Down From $194.00K YoY   Benzinga
Aug 3, 2020
09:18AM EDT  AEterna Zentaris Announces $7M Registered Direct Offering Priced At The Market   Benzinga
09:01AM EDT  AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING   GlobeNewswire Inc
Jul 31, 2020
07:36AM EDT  Aeterna Zentaris Announces Continued Expansion Of Intellectual Property Portfolio For Macimorelin With Additional Patent Applications   Benzinga
07:35AM EDT  Aeterna Zentaris Announces Continued Expansion of Intellectual   GlobeNewswire Inc
Jul 30, 2020
07:52AM EDT  Aeterna Zentaris Announces Abstract Of Results From First Pediatric Study Of Macimorelin Accepted For Presentation At The 22nd European Congress Of Endocrinology Sep. 5-9   Benzinga
07:35AM EDT  AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST   GlobeNewswire Inc
Jul 29, 2020
07:13AM EDT  Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; Says No Immediate Impact On Listing   Benzinga
07:05AM EDT  Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC